相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Three-year Efficacy and Safety of Takeda's Dengue Vaccine Candidate (TAK-003)
Luis Rivera et al.
CLINICAL INFECTIOUS DISEASES (2022)
Efficacy of a Dengue Vaccine Candidate (TAK-003) in Healthy Children and Adolescents 2 Years after Vaccination
Eduardo Lopez-Medina et al.
JOURNAL OF INFECTIOUS DISEASES (2022)
A phase I randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of a live-attenuated quadrivalent dengue vaccine in flavivirus-naive and flavivirus-experienced healthy adults
Kevin L. Russell et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2022)
Safety and immunogenicity of a single dose, live-attenuated 'tetravalent dengue vaccine' in healthy Indian adults; a randomized, double-blind, placebo controlled phase I/II trial
Lalitendu Mohanty et al.
VACCINE: X (2022)
Primary exposure to SARS-CoV-2 variants elicits convergent epitope specificities, immunoglobulin V gene usage and public B cell clones
Noemia S. Lima et al.
NATURE COMMUNICATIONS (2022)
Variability in Susceptibility to Type I Interferon Response and Subgenomic RNA Accumulation Between Clinical Isolates of Dengue and Zika Virus From Oaxaca Mexico Correlate With Replication Efficiency in Human Cells and Disease Severity
Tannya Karen Castro-Jimenez et al.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2022)
A combined fine needle aspiration and spectral flow cytometry approach to assess human germinal center responses to SARS-CoV-2 vaccination
Emily Bettini et al.
STAR PROTOCOLS (2022)
Analysis of Hospitalized and Severe Dengue Cases Over the 6 years of Follow-up of the Tetravalent Dengue Vaccine (CYD-TDV) Efficacy Trials in Asia and Latin America
Remi Forrat et al.
CLINICAL INFECTIOUS DISEASES (2021)
Designed, highly expressing, thermostable dengue virus 2 envelope protein dimers elicit quaternary epitope antibodies
Stephan T. Kudlacek et al.
SCIENCE ADVANCES (2021)
Global, regional, and national dengue burden from 1990 to 2017: A systematic analysis based on the global burden of disease study 2017
Zhilin Zeng et al.
ECLINICALMEDICINE (2021)
T Cell Responses Induced by Attenuated Flavivirus Vaccination Are Specific and Show Limited Cross-Reactivity with Other Flavivirus Species
Alba Grifoni et al.
JOURNAL OF VIROLOGY (2020)
Immunogenicity and Safety of a Tetravalent Recombinant Subunit Dengue Vaccine in Adults Previously Vaccinated with a Live Attenuated Tetravalent Dengue Vaccine: Results of a Phase-I Randomized Clinical Trial
Anna P. Durbin et al.
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE (2020)
Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial
Esper G. Kallas et al.
LANCET INFECTIOUS DISEASES (2020)
Sequential immunization induces strong and broad immunity against all four dengue virus serotypes
Jue Hou et al.
NPJ VACCINES (2020)
Zika virus infection enhances future risk of severe dengue disease
Leah C. Katzelnick et al.
SCIENCE (2020)
Dengue vaccine development by the year 2020: challenges and prospects
Annelies Wilder-Smith
CURRENT OPINION IN VIROLOGY (2020)
Slow Delivery Immunization Enhances HIV Neutralizing Antibody and Germinal Center Responses via Modulation of Immunodominance
Kimberly M. Cirelli et al.
CELL (2019)
The current and future global distribution and population at risk of dengue
Jane P. Messina et al.
NATURE MICROBIOLOGY (2019)
High-Throughput Mapping of B Cell Receptor Sequences to Antigen Specificity
Ian Setliff et al.
CELL (2019)
Dengue type 1 viruses circulating in humans are highly infectious and poorly neutralized by human antibodies
Rajendra Raut et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Broadly neutralizing human antibodies against dengue virus identified by single B cell transcriptomics
Natasha D. Durham et al.
ELIFE (2019)
Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Path to a Dengue Vaccine: Learning from Human Natural Dengue Infection Studies and Vaccine Trials
Aravinda M. de Silva et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2018)
Early Transcriptional Responses After Dengue Vaccination Mirror the Response to Natural Infection and Predict Neutralizing Antibody Titers
Stephen J. Popper et al.
JOURNAL OF INFECTIOUS DISEASES (2018)
Decreased accumulation of subgenomic RNA in human cells infected with vaccine candidate DEN4 Delta 30 increases viral susceptibility to type I interferon
Jose Bustos-Arriaga et al.
VACCINE (2018)
Quantification of dengue virus specific T cell responses and correlation with viral load and clinical disease severity in acute dengue infection
Dulharie T. Wijeratne et al.
PLOS NEGLECTED TROPICAL DISEASES (2018)
Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches
Matthias Pauthner et al.
IMMUNITY (2017)
Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study
Xavier Saez-Llorens et al.
LANCET INFECTIOUS DISEASES (2017)
Simultaneous epitope and transcriptome measurement in single cells
Marlon Stoeckius et al.
NATURE METHODS (2017)
In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination
Stephen S. Whitehead et al.
PLOS NEGLECTED TROPICAL DISEASES (2017)
The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model
Beth D. Kirkpatrick et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Antibody-Dependent Enhancement of Dengue Virus Infection in Primary Human Macrophages; Balancing Higher Fusion against Antiviral Responses
Jacky Flipse et al.
SCIENTIFIC REPORTS (2016)
Human CD8+ T-Cell Responses Against the 4 Dengue Virus Serotypes Are Associated With Distinct Patterns of Protein Targets
Daniela Weiskopf et al.
JOURNAL OF INFECTIOUS DISEASES (2015)
Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults
Beth D. Kirkpatrick et al.
JOURNAL OF INFECTIOUS DISEASES (2015)
Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition
Christopher J. L. Murray et al.
LANCET (2015)
Recognition determinants of broadly neutralizing human antibodies against dengue viruses
Alexander Rouvinski et al.
NATURE (2015)
Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study
Jorge E. Osorio et al.
LANCET INFECTIOUS DISEASES (2014)
Evaluation of Dengue Virus strains for human challenge studies
M. P. Mammen et al.
VACCINE (2014)
Experimental Dengue Virus Challenge of Human Subjects Previously Vaccinated With Live Attenuated Tetravalent Dengue Vaccines
Wellington Sun et al.
JOURNAL OF INFECTIOUS DISEASES (2013)
Epidemiological studies on dengue virus type 3 in Playa municipality, Havana, Cuba, 2001-2002
Maria G. Guzman et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2012)
Heterotypic Dengue Infection with Live Attenuated Monotypic Dengue Virus Vaccines: Implications for Vaccination of Populations in Areas Where Dengue Is Endemic
Anna P. Durbin et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine
Anna P. Durbin et al.
VACCINE (2011)
A Novel Tetravalent Dengue Vaccine Is Well Tolerated and Immunogenic against All 4 Serotypes in Flavivirus-Naive Adults
Dennis Morrison et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
Tropism of Dengue Virus in Mice and Humans Defined by Viral Nonstructural Protein 3-Specific Immunostaining
Scott J. Balsitis et al.
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE (2009)
Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3′ untranslated region (3′-UTR) or by exchange of the DENV-3 3′-UTR with that of DENV-4
Joseph E. Blaney et al.
VACCINE (2008)
Analysis of repeat hospital admissions for dengue to estimate the frequency of third or fourth dengue infections resulting in admissions and dengue hemorrhagic fever, and serotype sequences
Robert V. Gibbons et al.
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE (2007)
Genetically modified, live attenuated dengue virus type 3 vaccine candidates
JE Blaney et al.
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE (2004)
分享论文
